Precigen director gains 71,839 shares via RSU vesting
PRECIGEN, INC. director James S. Turley reported the vesting and conversion of restricted stock units into common shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
PRECIGEN, INC. director James S. Turley reported the vesting and conversion of restricted stock units into common shares. On March 13, 2026, 71,839 restricted stock units vested in full and were exercised, delivering 71,839 shares of common stock at no cash exercise price.
Following this compensation-related transaction, Turley directly owned 685,417 shares of Precigen common stock. The filing reflects an increase in equity holdings through RSU vesting rather than any open-market purchase or sale.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 71,839 | $0.00 | $0.00 |
| Exercise | Common Stock | 71,839 | $0.00 | $0.00 |
Footnotes (2)
- F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.
- F2. The RSUs vested in full on March 13, 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Precigen (PGEN) director James S. Turley report?
What are restricted stock units (RSUs) in the context of Precigen (PGEN)?
Did the Precigen (PGEN) Form 4 show any open-market buying or selling by James S. Turley?
AI-generated analysis. How Rhea-AI works. Not financial advice.